A panel of unique PDXs from clinical tumour samples were established and used to study metronomic gemcitabine’s treatment effects and the interactions between tumour stroma and cancer cells in situ. The original tumour lines have been merged into the BC Pancreatic Centre’s (BCPC) xenograft and in vitro bank of pancreatic cancer related biological matter. New tumour lines are being established, characterized and linked to the patient’s treatment history and outcome. The tumour lines are available freely to Scientists interested in pancreatic cancer research through the BCPC.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.